Petros Pharmaceuticals (PTPI) Short Interest Ratio & Short Volume → Biden replacement revealed? (From Paradigm Press) (Ad) Free PTPI Stock Alerts $0.68 -0.01 (-1.44%) (As of 05/7/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Petros Pharmaceuticals Short Interest DataCurrent Short Volume69,800 sharesPrevious Short Volume146,200 sharesChange Vs. Previous Month-52.26%Dollar Volume Sold Short$54,660.38Short Interest Ratio / Days to Cover0.1Last Record DateApril 15, 2024Outstanding Shares6,880,000 sharesFloat Size4,140,000 sharesShort Percent of Float1.69%Today's Trading Volume80,576 sharesAverage Trading Volume879,547 sharesToday's Volume Vs. Average9% Short Selling Petros Pharmaceuticals ? Sign up to receive the latest short interest report for Petros Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatPTPI Short Interest Over TimePTPI Days to Cover Over TimePTPI Percentage of Float Shorted Over Time Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. Petros Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202469,800 shares $54,660.38 -52.3%1.7%0.1 $0.78 3/31/2024146,200 shares $216,376.00 +65.4%3.6%0.1 $1.48 3/15/202488,400 shares $134,368.00 -72.1%6.8%0.1 $1.52 2/29/2024317,200 shares $545,584.00 +12.3%24.2%0.3 $1.72 2/15/2024282,400 shares $434,896.00 +16.5%21.9%0.3 $1.54 1/31/2024242,400 shares $293,304.00 +2,208.6%18.8%0.4 $1.21 Get the Latest News and Ratings for PTPI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/202410,500 shares $13,807.50 -74.8%0.8%0 $1.32 12/31/202341,700 shares $58,797.00 -66.5%3.1%0.2 $1.41 12/15/2023124,300 shares $172,777.00 +571.9%9.1%0.6 $1.39 11/30/202318,500 shares $29,600.00 -28.3%1.4%0.2 $1.60 11/15/202325,800 shares $34,314.00 -41.6%2.0%0.8 $1.33 10/31/202344,200 shares $63,206.00 -27.9%3.5%1.3 $1.43 10/15/202361,300 shares $98,073.87 +415.1%4.9%1.4 $1.60 9/30/202311,900 shares $20,585.81 +213.2%0.9%0 $1.73 9/15/20233,800 shares $6,878.00 -82.3%0.3%0 $1.81 8/31/202321,500 shares $54,825.00 -62.7%1.7%0.1 $2.55 8/15/202357,700 shares $184,640.00 -21.9%3.9%0.2 $3.20 7/31/202373,900 shares $296,339.00 -79.4%5.0%0.2 $4.01 7/15/2023359,100 shares $1.14 million +1,330.7%24.3%0.5 $3.19 6/30/202325,100 shares $50,953.00 -27.0%1.7%0 $2.03 6/15/202334,400 shares $89,784.00 -10.7%2.3%0 $2.61 5/31/202338,500 shares $89,705.00 -13.5%2.6%0 $2.33 5/15/202344,500 shares $186,900.00 -88.5%3.0%0 $4.20 4/30/2023385,300 shares $1.66 million +1,029.9%27.3%0.2 $4.30 4/15/202334,100 shares $156,519.00 -22.5%2.4%0 $4.59 3/31/202344,000 shares $61,380.00 +14.9%3.1%3.1 $1.40 3/15/202338,300 shares $56,684.00 +13.0%2.7%2.1 $1.48 2/28/202333,900 shares $71,190.00 -6.6%2.4%1.6 $2.10 2/15/202336,300 shares $92,202.00 +23.1%2.5%1.8 $2.54 1/31/202329,500 shares $76,700.00 -24.4%2.1%1.5 $2.60 1/15/202339,000 shares $118,950.00 +14.0%2.7%1.6 $3.05 12/30/202234,200 shares $79,686.00 +14.8%2.4%1.4 $2.33 12/15/202229,800 shares $63,176.00 +43.3%2.1%1.8 $2.12 11/30/202220,800 shares $8,550.88 -92.2%1.4%1.5 $0.41 11/15/2022265,700 shares $130,193.00 +78.6%N/A2.1 $0.49 10/31/2022148,800 shares $71,424.00 +9.3%N/A1 $0.48 10/15/2022136,200 shares $58,525.14 +77.3%N/A0.2 $0.43 9/30/202276,800 shares $39,168.00 -36.1%N/A0.1 $0.51 9/15/2022120,200 shares $78,682.92 -7.1%N/A0.1 $0.65 8/31/2022129,400 shares $84,821.70 +45.4%N/A0.1 $0.66Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. PTPI Short Interest - Frequently Asked Questions What is Petros Pharmaceuticals' current short interest? Short interest is the volume of Petros Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 69,800 shares of PTPI short. 1.69% of Petros Pharmaceuticals' shares are currently sold short. Learn More on Petros Pharmaceuticals' current short interest. What is a good short interest percentage for Petros Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.69% of Petros Pharmaceuticals' floating shares are currently sold short. Is Petros Pharmaceuticals' short interest increasing or decreasing? Petros Pharmaceuticals saw a decline in short interest in April. As of April 15th, there was short interest totaling 69,800 shares, a decline of 52.3% from the previous total of 146,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Petros Pharmaceuticals' float size? Petros Pharmaceuticals currently has issued a total of 6,880,000 shares. Some of Petros Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Petros Pharmaceuticals currently has a public float of 4,140,000 shares. How does Petros Pharmaceuticals' short interest compare to its competitors? 1.69% of Petros Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Petros Pharmaceuticals: Lipella Pharmaceuticals Inc. (1.49%), Exicure, Inc. (2.01%), Artelo Biosciences, Inc. (0.19%), NexImmune, Inc. (0.89%), Bright Minds Biosciences Inc. (2.76%), Oragenics, Inc. (2.07%), Cingulate Inc. (0.58%), Ensysce Biosciences, Inc. (0.14%), Genprex, Inc. (2.69%), Longeveron Inc. (9.34%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Petros Pharmaceuticals stock? Short selling PTPI is an investing strategy that aims to generate trading profit from Petros Pharmaceuticals as its price is falling. PTPI shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Petros Pharmaceuticals? A short squeeze for Petros Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PTPI, which in turn drives the price of the stock up even further. How often is Petros Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTPI, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Lipella Pharmaceuticals Short Squeeze Exicure Short Squeeze Artelo Biosciences Short Squeeze NexImmune Short Squeeze Bright Minds Biosciences Short Squeeze Oragenics Short Squeeze Cingulate Short Squeeze Ensysce Biosciences Short Squeeze Genprex Short Squeeze Longeveron Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PTPI) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe asset beating inflation by 4xColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldElon Musk Secret Crypto Plot ExposedCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsObama’s Forever Term [exposed]Porter & CompanyPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyProtect Your Bank Account Before It’s Too LateWeiss Ratings